$18.07
+0.69(3.94%)
Mkt Cap $124M
$3.03
$53.40
52-Week Range
At a Glance
AI-generatedVor Biopharma reported widened FY2025 operating and net losses, driven by restructuring costs and clinical investments, with liquidity to fund operations into early 2029.
8-K
Vor Biopharma Inc. entered into a Securities Purchase Agreement with entities affiliated with TCGX for a private placement of 5,338,078 shares of common stock at $14.05 per share, raising approximately $75.0 million in gross proceeds. The company intends to use the net proceeds to advance development of its clinical pipeline and for general corporate purposes.$124M
Market Cap
—
Revenue
-$2.5B
Net Income
Employees159
Fundamentals
How The Business Makes Money
Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers. Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Industry Biotechnology
Activity
What Changed Recently
Analyst View
Company Profile
CIK0001817229
ISINUS9290332074
CUSIP929033207
Phone617 655 6580
Address100 Cambridgepark Drive, Cambridge, MA, 02140, US
SEC EDGAR